US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Carlsmed, Inc. (CARL) priced a full-size deal of 6.7mm shares at $15.00 (midpoint of the range) and opened at $15.00.</li>
<li>There were concerns with the color coming from the book as the underwriters failed to provide price guidance to investors the day of pricing on the deal.</li>
<li>Given that the deal "broke" on day one, we believe investors "may" be turned off by the company in the short term.</li>
</ul>


Carlsmed, Inc. (CARL) priced a full-size deal of 6.7mm shares at $15.00 (midpoint of the range) and opened at $15.00.
There were concerns with the color coming from the book as the underwriters failed to provide price guidance to investors the day of pricing on the deal.
Given that the deal "broke" on day one, we believe investors "may" be turned off by the company in the short term.


Carlsmed Inc. (CARL): MedTech Makes Uninspiring Debut, Opens Flat and Trades Below Issue

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Artificial-Intelligence-Powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the company is seeking a market value of $430M.</li>
<li>Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is developing aprevo for cervical spine fusion surgeries, which is expected to be commercialized in 2026.</li>
<li>Carlsmed estimates there is a total addressable market of $13.4B for aprevo in the U.S. Aprevo may also benefit other musculoskeletal applications beyond the spine, unlocking greater market potential.</li>
</ul>


Artificial-Intelligence-Powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the company is seeking a market value of $430M.
Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is developing aprevo for cervical spine fusion surgeries, which is expected to be commercialized in 2026.
Carlsmed estimates there is a total addressable market of $13.4B for aprevo in the U.S. Aprevo may also benefit other musculoskeletal applications beyond the spine, unlocking greater market potential.


Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain

<ul>
<li>AI-Enabled personalized spine surgery solutions is set to debut on Wednesday, July 23rd.</li>
<li>Channel checks just completed, are currently revealing, according to guidance, multiple-times oversubscribed with continued long-only conversions.</li>
<li>Based on the flash numbers released in the prospectus of $12.0m in Q2 revenue, the growth for the year would be roughly 77% which are highly-attractive figures.</li>
</ul>


AI-Enabled personalized spine surgery solutions is set to debut on Wednesday, July 23rd.
Channel checks just completed, are currently revealing, according to guidance, multiple-times oversubscribed with continued long-only conversions.
Based on the flash numbers released in the prospectus of $12.0m in Q2 revenue, the growth for the year would be roughly 77% which are highly-attractive figures.


Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

<ul>
<li>Carlsmed is offering 6.7mm shares at $14.00-$16.00 equating to a market cap of $371m-$424m and is scheduled to debut on July 23rd</li>
<li>B Capital Group and U.S. Venture Partners have indicated an interest in purchasing up to approximately $20 million and $11 million, respectively.</li>
<li>MedTech companies like CarlsMed are easy to digest for IPO investors as the company typically sees sales in a strong trajectory going into the IPO.</li>
</ul>


Carlsmed is offering 6.7mm shares at $14.00-$16.00 equating to a market cap of $371m-$424m and is scheduled to debut on July 23rd
B Capital Group and U.S. Venture Partners have indicated an interest in purchasing up to approximately $20 million and $11 million, respectively.
MedTech companies like CarlsMed are easy to digest for IPO investors as the company typically sees sales in a strong trajectory going into the IPO.


Carlsmed, Inc. (CARL): MedTech Targeting the Spine Sets Terms for IPO

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>Omada Health is expected to IPO this week. The company’s amended prospectus puts the expected price range per share at $18 to $20, implying a market cap of ~$1.1B.</li>
<li>Omada Health is a virtual-first healthcare provider, supporting people with chronic conditions: prediabetes, diabetes (T2D), hypertension, obesity and musculoskeletal.</li>
<li>A digital care provider stayed private for longer. Its direct competitor, Livongo Health, went public in 2019 and was acquired by Teladoc Health for ~$18.5B in 2020.</li>
</ul>


Omada Health is expected to IPO this week. The company’s amended prospectus puts the expected price range per share at $18 to $20, implying a market cap of ~$1.1B.
Omada Health is a virtual-first healthcare provider, supporting people with chronic conditions: prediabetes, diabetes (T2D), hypertension, obesity and musculoskeletal.
A digital care provider stayed private for longer. Its direct competitor, Livongo Health, went public in 2019 and was acquired by Teladoc Health for ~$18.5B in 2020.


Omada Health IPO: Stayed Private For Longer, Modest Upside Potential

United States

Beta Bionics, Inc. is a commercial-stage medical device company. The Company offers an automated insulin delivery system with closed-loop algorithms for the treatment of people with diabetes. Beta Bionics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Beta Bionics (BBNX US)

Carlsmed Inc. (CARL): MedTech Makes Uninspiring Debut, Opens Flat and Trades Below Issue

Carlsmed, Inc. priced a full-size deal at $15.00 per share, opening at the same price, The stock traded lower on day one and closed at $14.50.

IPO Boutique

Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

AI-enabled personalized spine surgery solutions launching on July 23rd, with strong investor interest and projected 77% revenue growth for the year.

IPO Boutique

Carlsmed, Inc. (CARL): MedTech Targeting the Spine Sets Terms for IPO

Carlsmed set to debut on July 23rd with 6.7mm shares offered at $14.00-$16.00, attracting interest from B Capital Group and U.S. Venture Partners.

IPO Boutique

Omada Health IPO: Stayed Private For Longer, Modest Upside Potential

Omada Health, a virtual healthcare provider for chronic conditions, set to IPO with expected price range of $18 to $20 per share, aiming for a...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Carlsmed Inc. (CARL): MedTech Makes Uninspiring Debut, Opens Flat and Trades Below Issue

​Carlsmed, Inc. priced a full-size deal at $15.00 per share, opening at the same price, The stock traded lower on day one and closed at $14.50.

IPO Boutique

Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain

Artificial-intelligence-powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the...

Tina Banerjee

Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

​AI-enabled personalized spine surgery solutions launching on July 23rd, with strong investor interest and projected 77% revenue growth for the year.

IPO Boutique

Carlsmed, Inc. (CARL): MedTech Targeting the Spine Sets Terms for IPO

​Carlsmed set to debut on July 23rd with 6.7mm shares offered at $14.00-$16.00, attracting interest from B Capital Group and U.S. Venture Partners.

IPO Boutique

Omada Health IPO: Stayed Private For Longer, Modest Upside Potential

​Omada Health, a virtual healthcare provider for chronic conditions, set to IPO with expected price range of $18 to $20 per share, aiming for a...

Andrei Zakharov

Carlsmed, Inc. priced a full-size deal at $15.00 per share, opening at the same price, The stock traded lower on day one and closed at $14.50.

AI-enabled personalized spine surgery solutions launching on July 23rd, with strong investor interest and projected 77% revenue growth for the year.

Carlsmed set to debut on July 23rd with 6.7mm shares offered at $14.00-$16.00, attracting interest from B Capital Group and U.S. Venture Partners.

Omada Health, a virtual healthcare provider for chronic conditions, set to IPO with expected price range of $18 to $20 per share, aiming for a...